77 results
Page 2 of 4
8-K
EX-10.1
8f2s76nz9km5gj
14 Jun 21
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.1
p8ivwqc
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-10.1
69embds1
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
EX-99.1
hzrwm
23 Jul 20
Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500
7:05am
8-K
EX-10.3
scx8wi
9 Jan 20
Aravive Announces Management Changes
4:59pm
8-K
EX-1.1
4mnht6nejff8 yhnv
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
8-K
EX-99.1
15fnfzkrh8u4hn34
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
8-K
EX-99.2
rcmnklnm9j7pgzfuz0u
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
S-8
EX-99.1
5843esjsn265ymmdu
20 Sep 19
Registration of securities for employees
4:09pm
8-K
EX-99.1
va1gg03negvn9ku5k9df
8 May 19
Aravive Reports First Quarter 2019 Financial Results and Provides Recent Corporate Updates
4:15pm
8-K
EX-1.1
2vjh8u7 4xk30huf9w7
26 Mar 19
Entry into a Material Definitive Agreement
6:07am
8-K
EX-99.1
fypq40f2lb4f5uei
7 Mar 19
Results of Operations and Financial Condition
4:16pm
8-K
EX-10.1
ip51p
20 Nov 18
Departure of Directors or Certain Officers
4:15pm